Participants 58 125 6
patients with relapsing-remitting multiple sclerosis: a multicentre
Participants 277 392 4
patients with relapsing-remitting multiple sclerosis was well tolerated and reduced the formation of active lesions
Participants 562 613 5
The study was done in 51 centres in nine countries.
Participants 614 842 16
Inclusion criteria were one or more relapses in the year before entry and at least one gadolinium enhancing (GdE) lesion on screening MRI. Of 720 patients screened, 306 eligible patients were enrolled. Patients, aged 18-50 years
